GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,636.00p
   
  • Change Today:
    -15.00p
  • 52 Week High: 1,711.20p
  • 52 Week Low: 1,316.00p
  • Currency: UK Pounds
  • Shares Issued: 4,144.88m
  • Volume: 3,447,340
  • Market Cap: £67,810m
  • RiskGrade: 129

GSK Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.
Registrars: Equiniti
Brands: Lucozade, Horlicks, Ribena, Paxil, Seroxat

Key Personnel

CEO: Emma Walmsley
Chief Finance Officer: Julie Brown
Independent Non-Executive Director: Elizabeth (Liz) McKee Anderson
Independent Non-Executive Director: Anne Beal
Independent Non-Executive Director: Urs Rohner
Independent Non-Executive Director: Harry (Hal) C. Dietz
Independent Non-Executive Director: Jesse Goodman
Independent Non-Executive Director: Vishal Sikka
Non-Executive Chairman: Jonathan Symonds
Senior Independent Non-Executive Director: Charles Bancroft
Non-Executive Dir: Jeannie Lee , Hal Barron , Wendy Becker

Contact Details

Address: 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS
Phone: +44 (0)20 8047 5000
Website: http://www.gsk.com

Listings

Sector: Pharma and Biotech(LSE)
Index: techMARK, FTSE 100, FTSE 350, FTSE All-Share
Overseas Listings: BATSLON:GSKL, NYSE:GSK
ISIN: GB00BN7SWP63

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,636.00p
Change Today -15.00p
% Change -0.91 %
52 Week High 1,711.20p
52 Week Low 1,316.00p
Volume 3,447,340
Shares Issued 4,144.88m
Market Cap £67,810m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
80.47% below the market average80.47% below the market average80.47% below the market average80.47% below the market average80.47% below the market average
81.13% below the sector average81.13% below the sector average81.13% below the sector average81.13% below the sector average81.13% below the sector average
Price Trend
29.70% above the market average29.70% above the market average29.70% above the market average29.70% above the market average29.70% above the market average
71.93% above the sector average71.93% above the sector average71.93% above the sector average71.93% above the sector average71.93% above the sector average
Income
44.11% above the market average44.11% above the market average44.11% above the market average44.11% above the market average44.11% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
24.54% below the market average24.54% below the market average24.54% below the market average24.54% below the market average24.54% below the market average
40.54% above the sector average40.54% above the sector average40.54% above the sector average40.54% above the sector average40.54% above the sector average

What The Brokers Say

Strong Buy 8
Buy 5
Neutral 9
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q4 Q3
Ex-Div 22-Feb-24 16-Nov-23
Paid 11-Apr-24 11-Jan-24
Amount 16.00p 14.00p

Trades for 24-Apr-2024

Time Volume / Share Price
16:35 1,685,159 @ 1,636.00p
16:35 3,275 @ 1,636.00p
16:35 7,889 @ 1,636.00p
16:35 814 @ 1,636.00p
16:35 385 @ 1,636.00p

GSK Key Personnel

CEO Emma Walmsley

Top of Page